Argent Biopharma Limited PDMR Notification
April 30 2024 - 10:01AM
RNS Regulatory News
RNS Number : 6689M
Argent Biopharma Limited
30 April 2024
30
April 2024
Argent BioPharma
Ltd
PDMR
Notification
Argent BioPharma Ltd (Argent BioPharma, RGT or the
Company), wishes to advise that the
following Persons Discharging Managerial Responsibilities (PDMR)
were issued a combined 68,000 unlisted options.
This notification is made in accordance the
UK Market Abuse Regulations.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Amir Polak
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Chief Pharmaceutical Development
Officer
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Ltd
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Unlisted options exercisable at
A$0.70 on or before 1 April 2029.
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Grant of Options over Ordinary
Shares
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.00
|
12,000
|
N/A
|
|
|
Aggregated
information
|
|
|
AUD
|
0.00
|
12,000
|
N/A
|
|
(e)
|
Date of transaction
|
26 April 2024
|
|
(f)
|
Place of transaction
|
Outside a trading venue
|
|
|
|
|
|
| |
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Yair Tal
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Chief Information Security
Officer
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Ltd
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Unlisted options exercisable at
A$0.70 on or before 1 April 2029.
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Grant of Options over Ordinary
Shares
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.00
|
8,000
|
N/A
|
|
|
Aggregated
information
|
|
|
AUD
|
0.00
|
8,000
|
N/A
|
|
(e)
|
Date of transaction
|
26 April 2024
|
|
(f)
|
Place of transaction
|
Outside a trading venue
|
|
|
|
|
|
| |
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Yifat Steuer
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Chief Operating Officer and Deputy
CEO
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Ltd
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Unlisted options exercisable at
A$0.70 on or before 1 April 2029.
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Grant of Options over Ordinary
Shares
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.00
|
15,000
|
N/A
|
|
|
Aggregated
information
|
|
|
AUD
|
0.00
|
15,000
|
N/A
|
|
(e)
|
Date of transaction
|
26 April 2024
|
|
(f)
|
Place of transaction
|
Outside a trading venue
|
|
|
|
|
|
| |
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Itay Nissim
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Chief Supply Chain Officer
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Ltd
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Unlisted options exercisable at
A$0.70 on or before 1 April 2029.
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Grant of Options over Ordinary
Shares
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.00
|
12,000
|
N/A
|
|
|
Aggregated
information
|
|
|
AUD
|
0.00
|
12,000
|
N/A
|
|
(e)
|
Date of transaction
|
26 April 2024
|
|
(f)
|
Place of transaction
|
Outside a trading venue
|
|
|
|
|
|
| |
-Ends-
Authorised for release by the Company Secretary, for further
information please contact:
About Argent BioPharma
Argent BioPharma purpose is to
address unmet medical needs through the pioneering integration of
Nanotechnology and Multidisciplinary research methods. Our approach
heralds a transformative shift in healthcare, combining the power
of multi-targeted drug therapies with precision nanoscale delivery
to enhance treatment efficacy while reducing side effects. Central
to our ethos is making these innovative treatments accessible,
ensuring they reach those underserved by current medical solutions.
As we endeavor to become globally recognized in the life science
industry, we are committed to bridging healthcare gaps, redefining
industry standards, and providing impactful solutions and hope to
communities worldwide.
Follow us through our social media channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHKZGFDDGLGDZM
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Apr 2024 to May 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From May 2023 to May 2024
